RA Capital Management 13F holdings, Q3 2012
Holdings as of September 30, 2012 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 21 US equity positions worth $197.7m in its Q3 2012 13F filing. The largest position was NVAX at 14.4% of the reported book, followed by DYAX CORP and ANACOR PHARMACEUTICALS INC. Against the Q2 2012 filing, it opened 3 new positions, added to 3 and reduced 6 among the top 21 holdings.
What did RA Capital Management own in Q3 2012? Top 21 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2012 |
|---|---|---|---|---|---|---|---|
| 1 | NVAX NOVAVAX INC | Healthcare | 14.4% | $28.5m | 13,200,000 | 0% | held |
| 2 | DYAX CORP | 11.2% | $22.2m | 8,528,940 | 0% | held | |
| 3 | ANACOR PHARMACEUTICALS INC | 8.5% | $16.7m | 2,543,758 | 6% | added | |
| 4 | SUNESIS PHARMACEUTICALS INC | 7.4% | $14.6m | 2,585,816 | – | new | |
| 5 | ARTHROCARE CORP | 7.2% | $14.2m | 439,186 | -22% | reduced | |
| 6 | DERMA SCIENCES INC | 6.6% | $13.0m | 1,253,419 | 0% | held | |
| 7 | SGMOQ SANGAMO BIOSCIENCES INC | Healthcare | 6.6% | $13.0m | 2,132,659 | -2% | reduced |
| 8 | XOMA CORP DEL | 5.8% | $11.4m | 3,095,115 | 1% | added | |
| 9 | ACAD ACADIA PHARMACEUTICALS INC | Healthcare | 5.7% | $11.2m | 4,417,583 | -13% | reduced |
| 10 | VNDA VANDA PHARMACEUTICALS INC | Healthcare | 4.8% | $9.5m | 2,354,793 | -9% | reduced |
| 11 | CORONADO BIOSCIENCES INC | 4.7% | $9.2m | 1,777,019 | 0% | held | |
| 12 | YM BIOSCIENCES INC | 2.9% | $5.8m | 3,163,974 | 0% | held | |
| 13 | SEQUENOM INC | 2.7% | $5.3m | 1,510,000 | 0% | held | |
| 14 | SENOMYX INC | 2.6% | $5.2m | 2,757,076 | 42% | added | |
| 15 | VSTM VERASTEM INC | Healthcare | 2.6% | $5.2m | 557,766 | -8% | reduced |
| 16 | VENTRUS BIOSCIENCES INC | 2.3% | $4.5m | 1,245,000 | 0% | held | |
| 17 | ANTHERA PHARMACEUTICALS INC | 1.5% | $2.9m | 2,939,971 | – | new | |
| 18 | TRANZYME INC | 1.1% | $2.1m | 467,533 | – | new | |
| 19 | MELA SCIENCES INC | 0.8% | $1.6m | 500,000 | 0% | held | |
| 20 | SYNERGY PHARMACEUTICALS DEL | 0.6% | $1.2m | 259,383 | -87% | reduced | |
| 21 | SAVIENT PHARMACEUTICALS INC | 0.1% | $250.0k | 1,000,000 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.